{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:17:48Z","timestamp":1791224268945,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.diagmicrobio.2006.12.014","type":"journal-article","created":{"date-parts":[[2007,2,10]],"date-time":"2007-02-10T07:13:30Z","timestamp":1171091610000},"page":"S5-S12","source":"Crossref","is-referenced-by-count":42,"special_numbering":"S","title":["Review of the spectrum and potency of orally administered cephalosporins and amoxicillin\/clavulanate"],"prefix":"10.1016","volume":"57","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Fritsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.otohns.2003.12.003","article-title":"Antimicrobial treatment guidelines for acute bacterial rhinosinusitis","volume":"130","author":"Anon","year":"2004","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.inf.0000202138.12950.3c","article-title":"A multicenter, open label, double tympanocentesis study of high dose cefdinir in children with acute otitis media at high risk of persistent or recurrent infection","volume":"25","author":"Arguedas","year":"2006","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib3","series-title":"Physicians' Desk Reference","first-page":"1421","author":"Augmentin","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.curtheres.2003.09.006","article-title":"Single-dose (30 mg\/kg) azithromycin compared with 10-day amoxicillin\/clavulanate for the treatment of uncomplicated acute otitis media: a double-blind, placebo-controlled, randomized clinical trial","volume":"64","author":"Block","year":"2003","journal-title":"Curr. Ther. Res."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib5","unstructured":"Block, S. L., Ferguson, B. J., Pfaller, M. A. (2006). Oral \u03b2-lactams in the treatment of acute otitis media (In this supplement)."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib6","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1097\/00006454-200012001-00003","article-title":"Five-day cefdinir course vs. ten-day cefprozil course for treatment of acute otitis media","volume":"19","author":"Block","year":"2000","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib7","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1185\/030079906X132406","article-title":"Efficacy, tolerability, and parent reported outcomes for cefdinir vs. high-dose amoxicillin\/clavulanate oral suspension for acute otitis media in young children","volume":"22","author":"Block","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0732-8893(91)90069-R","article-title":"In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin","volume":"14","author":"Briggs","year":"1991","journal-title":"Diagn. Microbiol. Inf. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib9","article-title":"Ricerche su di un nuovo antibiotico","author":"Brotzu","year":"1948","journal-title":"D'Igiene di Cagliari, Lavori dell'Instituto"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib10","first-page":"222","article-title":"Oral cephalosporins","volume":"1","author":"Bryskier","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib11","author":"British Society for Antimicrobial Chemotherapy (BSAC)"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib12","series-title":"Physician's Desk Reference","first-page":"1829","author":"Ceclor","year":"2004"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib13","series-title":"Physicians' Desk Reference","first-page":"1450","author":"Ceftin","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib14","series-title":"Physicians' Desk Reference","first-page":"1037","author":"Cefzil","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib15","series-title":"M7-A7, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard\u2014Seventh Edition","author":"Clinical and Laboratory Standards Institute","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib16","series-title":"M100-S16, Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement","author":"Clinical and Laboratory Standards Institute","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of \u03b2-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib18","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1473-3099(02)00394-8","article-title":"Bacterial eradication in the treatment of otitis media","volume":"2","author":"Dagan","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib19","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2165\/00003495-199244050-00011","article-title":"Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential","volume":"44","author":"Frampton","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0732-8893(92)90105-3","article-title":"Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines","volume":"15","author":"Gerlach","year":"1992","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib21","doi-asserted-by":"crossref","first-page":"828","DOI":"10.7164\/antibiotics.41.828","article-title":"FK 482, a new orally active cephalosporin synthesis and biological properties","volume":"41","author":"Inamoto","year":"1988","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib22","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1201-9712(03)90066-X","article-title":"How can we predict bacterial eradication?","volume":"7","author":"Jacobs","year":"2003","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/dkg321","article-title":"The Alexander Project 1998\u20132000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents","volume":"52","author":"Jacobs","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2006.11.020","article-title":"Oral \u03b2-lactams applied to uncomplicated infections of skin and skin structures","author":"Jacobs","year":"2007","journal-title":"Diagn Microbiol Inf Dis (In this supplement)"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.diagmicrobio.2006.04.015","article-title":"Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly?","volume":"55","author":"Jones","year":"2006","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib26","series-title":"Physicians' Desk Reference","first-page":"1871","author":"Keflex","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib27","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1097\/00006454-200012001-00009","article-title":"Summary: role of a new oral cephalosporin, cefdinir, for therapy of infections of infants and children","volume":"19","author":"Klein","year":"2000","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1469-0691.2000.tb02047.x","article-title":"The new oral cephalosporins in community-acquired infections","volume":"6","author":"Low","year":"2000","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0149-2918(00)88477-5","article-title":"Cefaclor revisited","volume":"22","author":"Meyers","year":"2000","journal-title":"Clin. Ther."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib30","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.7164\/antibiotics.41.1873","article-title":"In vitro antibacterial activity of FK482, a new orally active cephalosporin","volume":"41","author":"Mine","year":"1988","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1128\/AAC.26.2.174","article-title":"Comparative in vitro activity and \u03b2-lactamase stability of FR 17027, a new orally active cephalosporin","volume":"26","author":"Neu","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib32","series-title":"Physicians' Desk Reference","first-page":"506","author":"Omnicef","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib33","series-title":"Omnicef (cefdinir)","author":"Package insert","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib34","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2165\/00003495-200464130-00004","article-title":"Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections","volume":"64","author":"Perry","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.otohns.2003.12.002","article-title":"A mathematical therapeutic outcomes model for sinusitis","volume":"130","author":"Poole","year":"2004","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib36","doi-asserted-by":"crossref","first-page":"109S","DOI":"10.1592\/phco.2005.25.12part2.109S","article-title":"Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials","volume":"25","author":"Powers","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib37","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0732-8893(03)00165-2","article-title":"Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000\u20132002)","volume":"47","author":"Sader","year":"2003","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib38","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/106002809603000310","article-title":"Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten","volume":"30","author":"Schatz","year":"1996","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib39","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2165\/00003495-200161100-00008","article-title":"Cefuroxime axetil: an updated review of its use in the management of bacterial infections","volume":"61","author":"Scott","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib40","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/BF01961677","article-title":"Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, Gram-negative bacilli and respiratory tract pathogens","volume":"11","author":"Scriver","year":"1992","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.otohns.2003.12.003","article-title":"Executive summary (antimicrobial treatment guidelines for acute bacterial rhinosinusitis)","volume":"130","author":"Sinus and Allergy Health Partnership","year":"2004","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib42","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1093\/clinids\/14.Supplement_2.S189","article-title":"Review of the in vitro antibacterial activity of cefprozil, a new oral cephalosporin","volume":"14","author":"Thornsberry","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib43","series-title":"Physicians' Desk Reference","first-page":"2758","author":"Vantin","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib44","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/jac\/dkh050","article-title":"Augmentin (amoxicillin\/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent","volume":"53","author":"White","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib45","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1128\/AEM.15.4.765-769.1967","article-title":"Cephalexin, a new orally absorbed cephalosporin antibiotic","volume":"15","author":"Wick","year":"1967","journal-title":"Appl. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib46","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/jac\/28.2.239","article-title":"The in-vitro activity of cefdinir (FK482), a new oral cephalosporin","volume":"28","author":"Wise","year":"1991","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.12.014_bib47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/00003495-199345020-00008","article-title":"Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential","volume":"45","author":"Wiseman","year":"1993","journal-title":"Drugs"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889306005219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889306005219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T22:25:59Z","timestamp":1587335159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889306005219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0732889306005219"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2006.12.014","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}